Galera Therapeutics, Inc.
GRTX
$0.02
$0.00-6.62%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -62.02% | -62.18% | -39.46% | -14.70% | -31.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.65% | -73.03% | -57.11% | -68.64% | -66.23% |
| Operating Income | 61.65% | 73.03% | 57.11% | 68.64% | 66.23% |
| Income Before Tax | 76.00% | 73.55% | 63.66% | 11.74% | 61.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.13% | 73.55% | 63.66% | 11.74% | 62.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.13% | 73.55% | 63.66% | 11.74% | 62.97% |
| EBIT | 61.65% | 73.03% | 57.11% | 68.64% | 66.23% |
| EBITDA | 61.73% | 73.11% | 57.14% | 67.28% | 66.24% |
| EPS Basic | 86.26% | 85.41% | 79.88% | 13.24% | 69.04% |
| Normalized Basic EPS | 78.85% | 85.44% | 79.92% | 80.84% | 76.28% |
| EPS Diluted | 86.26% | 85.41% | 79.88% | 13.24% | 69.04% |
| Normalized Diluted EPS | 78.85% | 85.44% | 79.92% | 80.84% | 76.28% |
| Average Basic Shares Outstanding | 81.10% | 81.10% | 81.10% | 1.79% | 19.60% |
| Average Diluted Shares Outstanding | 81.10% | 81.10% | 81.10% | 1.79% | 19.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |